BHWM
VRTX icon

Beaird Harris Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Beaird Harris Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Hold
33
– – ﹤0.01% 353
2026
Q1 		$14.7K Hold
33
– – ﹤0.01% 339
2025
Q4 		$15K Hold
33
– – ﹤0.01% 368
2025
Q3 		$12.9K Buy
33
+5
+18% +$2.09K ﹤0.01% 365
2025
Q2 		$12.5K Buy
28
+14
+100% +$6.45K ﹤0.01% 365
2025
Q1 		$6.79K Buy
14
+5
+56% +$2.33K ﹤0.01% 365
2024
Q4 		$3.63K Hold
9
– – ﹤0.01% 395
2024
Q3 		$4.19K Hold
9
– – ﹤0.01% 387
2024
Q2 		$4.22K Hold
9
– – ﹤0.01% 463
2024
Q1 		$3.76K Hold
9
– – ﹤0.01% 418
2023
Q4 		$3.66K Buy
+9
New +$3.33K ﹤0.01% 412
2023
Q1 		– Sell
-62
Closed -$17.9K – 744
2022
Q4 		$17.9K Buy
+62
New +$18.9K ﹤0.01% 270

Other funds holding VRTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
BHIA
Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return
CTB
Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
GIA
Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return
II
IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

Beaird Harris Wealth Management's VRTX Position: Q2 2026 in Review

Beaird Harris Wealth Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 33 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #353.

Beaird Harris Wealth Management first reported a position in VRTX in Q4 2022 and has held it in 12 quarters since. The position peaked at $17.9K in Q4 2022. 330 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Beaird Harris Wealth Management held 33 shares of Vertex Pharmaceuticals worth $16.4K as of Q2 2026.
  • Beaird Harris Wealth Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Beaird Harris Wealth Management's portfolio in Q2 2026, its #353 holding.
  • Beaird Harris Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 12 quarters since.
  • Beaird Harris Wealth Management's Vertex Pharmaceuticals position peaked at $17.9K in Q4 2022.
  • 330 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Beaird Harris Wealth Management's 13F filing for Q2 2026, filed 8 Jul 2026.